Skip to main content
STARPHARMA HOLDINGS LIMITED logo

STARPHARMA HOLDINGS LIMITED — Investor Relations & Filings

Ticker · SPL ISIN · AU000000SPL0 LEI · 254900WRGE3OUSWGMB55 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,316 across all filing types
Latest filing 2024-10-17 Regulatory Filings
Country AU Australia
Listing ASX SPL

About STARPHARMA HOLDINGS LIMITED

https://starpharma.com/

Starpharma Holdings Limited is a biopharmaceutical company focused on the development of dendrimer technology for pharmaceutical and life science applications. The company utilizes its proprietary DEP® (Dendrimer Enhanced Product) delivery platform to improve the performance of existing drugs by enhancing solubility, reducing toxicity, and providing targeted delivery. Its clinical-stage internal pipeline includes DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, primarily targeting oncology. Starpharma also markets VivaGel® BV, a non-antibiotic treatment and prevention for bacterial vaginosis, and VIRALEZE™, an antiviral nasal spray containing astodrimer sodium. The company collaborates with global pharmaceutical firms to apply its dendrimer technology to various therapeutic areas, including antibody-drug conjugates and radiopharmaceuticals.

Recent filings

Filing Released Lang Actions
SPL7013 Nasal Spray Australia Update 2 pages 171.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Starpharma Holdings Limited dated 18 October 2024. It discusses the withdrawal of an application for marketing authorization of a product (SPL7013 Nasal Spray) in Australia. The content focuses on a strategic business decision and regulatory update rather than financial results, management changes, or detailed financial data. There is no indication of financial statements, earnings data, or detailed report content. The document is a formal announcement about a regulatory and strategic update, typical of a Regulatory Filing (RNS). The document length is 6745 characters, which is sufficient for a full report, but the content is clearly an announcement rather than a full report or detailed financial disclosure. Therefore, the best classification is Regulatory Filings (RNS).
2024-10-17 English
Notification of cessation of securities - SPL 4 pages 14.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Starpharma Holdings Limited regarding the cessation (lapse) of certain performance rights securities. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The content focuses on changes in the company's issued capital and securities, specifically the lapse of conditional rights under an employee incentive scheme. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about securities changes, fitting the category of Share Issue/Capital Change (SHA). The document length is 4029 characters, which is consistent with a detailed announcement rather than a full report.
2024-10-02 English
Date of Annual General Meeting 2024 1 page 145.3KB
AGM Information Classification · 95% confidence The document is an ASX announcement dated 3 October 2024 from Starpharma regarding the date of its 2024 Annual General Meeting (AGM). It specifies the AGM date, nomination closing date for director elections, and mentions that details will be provided in the Notice of Meeting. It also states that the Chair's address and CEO's presentation will be released before the AGM. The document does not contain the actual AGM materials or presentations but is an announcement about the AGM date and related procedural information. The document length is 5337 characters, which is relatively short and consistent with an announcement rather than a full report or presentation. Therefore, this document fits the category of AGM Information (AGM-R) as it relates to the AGM event and its scheduling, not the full AGM materials or reports themselves.
2024-10-02 English
Change of Director's Interest Notice - Dr Russell Basser 2 pages 308.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's acquisition of shares, including dates, number of shares before and after the transaction, and the nature of the transaction (on-market purchase). This is a report of personal share transactions by a company director. It is not an annual report, earnings release, or any other type of financial or regulatory report. The document fits the definition of 'Director's Dealing' (DIRS) as it reports insider trades by a director.
2024-09-15 English
Starpharma Receives $5.5M R&D Tax Incentive Refund 2 pages 137.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Starpharma about receiving a $5.5 million R&D Tax Incentive refund for the 2024 financial year. It discusses the nature of the refund, the company's R&D activities, and includes forward-looking statements. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is a corporate announcement about a tax incentive refund, not a financial report, audit, or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category as it informs investors and the public about a material financial event (receipt of a tax refund) but does not constitute a formal financial report or filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-09-11 English
Ceasing to be a substantial holder 4 pages 245.5KB
Major Shareholding Notification Classification · 100% confidence The document is a formal notice under the Corporations Act 2001 Section 671B titled 'Notice of ceasing to be a substantial holder.' It details changes in substantial shareholding interests, including dates, parties involved, and related entities. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of a Major Shareholding Notification. The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about shareholding changes. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2024-09-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.